Chimerix, Inc. (NASDAQ:CMRX) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET

Company Participants

Michelle Laspaluto - Vice President of Strategic Planning & Investor Relations

Mike Andriole - President & Chief Executive Officer

Josh Allen - Chief Technology Officer

Allen Melemed - Chief Medical Officer

Conference Call Participants

Naureen Quibria - Capital One

Soumit Troy - Jones Research

Troy Langford - TD Cowen

Operator

Good morning, ladies and gentlemen, and welcome to the Chimerix Third Quarter 2023 Earnings Conference Call.

I would now like to introduce you to your host for today's call, Michelle Laspaluto, Vice President of Strategic Planning and Investor Relations at Chimerix. Please proceed.

Michelle Laspaluto

Thank you, John. Good morning, everyone, and welcome to the Chimerix third quarter 2023 financial and operating results conference call. This morning, we issued a press release related to our third quarter update. You can access the press release in our Investors section of the website.

With me on today's call are President and Chief Executive Officer, Mike Andriole; Chief Medical Officer, Allen Melemed; and Chief Technology Officer, Josh Allen.

Before we begin, I'd like to remind you that the statements made on today's call include forward-looking statements within the meaning of Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties and other factors. These risks and uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. Please refer to our filings with the SEC for a more complete disclosure of these risks and uncertainties.

At this time, I would now like to turn the call over to our President and Chief Executive Officer, Mike Andriole.

Mike Andriole

Thank you, Michelle, and good morning, everyone. The third quarter was marked by continued execution across our pipeline including continued enrollment in our global Phase 3 ACTION study of ONC201 and Phase 1 dose escalation studies for our second-generation compound, ONC206.

I'll start with ONC201 in the ACTION study. We now have 113 sites open across 12 countries and tracking ahead of our prior guidance of activating 100 sites by September 30. Enrollment is progressing with site activation, and we continue to expect first and second interim overall survival data as well as PFS data in 2025.

Geographically, we now have about an equal number of sites activated in Europe as the US. This past September, we participated in the European Association for Neuro-Oncology Conference, also known as EANO in the Netherlands. And at that conference, we hosted a symposium on the current diagnosis, treatment strategies and clinical trials for H3 K27M mutant glioma and engaged with the neuro-oncology community broadly to drive ongoing awareness and interest in the ACTION study.